NCT00943293

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia (GVL) responses without causing graft-versus-host disease (GVHD).

Conditions

• Preleukemia
• Myeloproliferative Disorders
• Lymphoma
• Myeloma
• Graft Versus Host Disease

Interventions

Type	Name	Description
DRUG	Fludarabine	Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
DRUG	Melphalan	Melphalan 140 mg/m2 IV on day -2.
DRUG	Campath	Campath, 20 mg IV on day -7, 6, -5, -4, and -3.

Timeline

• Start date: 2003-05-01
• Primary completion: 2011-09-01
• Completion: 2012-01-01
• First posted: 2009-07-22
• Last updated: 2014-03-17

Locations

1 site across 1 country: United States